HOME >> BIOLOGY >> NEWS
St. Jude ranked among top 500 supercomputer centers

collection to discovery of important new findings."

"The Hartwell Center is dedicated to research that will benefit children, and in the long run, the research will benefit all people who suffer from some of the same catastrophic diseases that threaten children around the world," Naeve said. "In that sense, although this is a St. Jude resource, it will produce knowledge that will be a resource for the entire world."

"Our goal is to help St. Jude use information technology to quicken the pace of clinical research into children's diseases," said James Coffin, Ph.D., vice president, IBM Life Sciences. "The selection of the right technology was very important to St. Jude because of the complexity of the projects and the volume of data that researchers are dealing with in their investigations. We are very pleased that they chose IBM's BladeCenter for their computing needs."

One of the St. Jude projects uses the new computing power to study the motion of enzyme molecules in order to determine how these proteins work, and how mutations in them change or destroy their ability to do their jobs, Naeve said. Enzymes are large proteins that control the speed of specific biochemical reactions in the body. Many diseases are caused by malfunctioning enzymes.

"Shape is everything to a protein," Naeve said. "Mutations that change a protein's shape can derail the protein's function and disrupt the normal function of the cell. And the shape of a potential drug molecule determines whether it will interact properly with its target in the body."

A second project that has benefited from the supercomputer is the study of the flexibility of a tumor suppressor protein called p27, and how the flexibility affects the protein's function. The supercomputer cut computation time from 200 hours to just 20. Another project that is benefiting from the supercomputer is a study that screens various molecules to determine if they might be effective drugs agai
'"/>

Contact: Bonnie Cameron
bonnie.cameron@stjude.org
901-495-4815
St. Jude Children's Research Hospital
22-Dec-2003


Page: 1 2 3

Related biology news :

1. Cleaner water, more efficient electricity among UH chemical research
2. Alcohol-use and depression among pregnant and postpartum women
3. Parents are top influence on soft-drink consumption among kids
4. University of Pittsburgh medical center among first to implant heart assist device
5. Professor and student among tops in technology at UH
6. UCSD study shows how we perceive world depends on precise division of labor among cells in brain
7. Chronic respiratory symptoms prevalent among Alaska natives
8. Specifying alcohol-related brain-damage among heavy social drinkers
9. Researchers identify unifying code among diverse classes of natural antibiotics
10. Marsupial among model organisms next in line for sequencing
11. Mastectomy dramatically reduces breast cancer risk among women with BRCA1/2 mutations

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Jude ranked among top supercomputer centers

(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
(Date:10/17/2014)... release is available in German . ... of sperms every day in order to reproduce? And why ... the topic of the latest issue of the research journal ... The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has ... is not unusual for a female to copulate with several ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
Cached News: